FDA slaps Bioptigen with warning over marketing claims
February 16, 2011 by MedCity News
Bioptigen receives a warning letter from the Food & Drug Administration that says the medical imaging firm is marketing its eye imaging scanner without proper regulatory approvals.
Medical imaging technology company Bioptigen received a warning from the Food & Drug Administration alleging that the company is marketing its eye imaging scanner without proper approvals.
The Research Triangle Park, N.C.-based company makes a medical device that allows for imaging of the inner areas of the eye. The company has marketed the product for research as well as medical applications.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- When regulators are ignored
- FDA Issues Draft Guidance to Help Companies Distinguish Between a Voluntary Medical Device Recall and a Product Enhancement
- Patient and family engagement in ICUs
- A day in the life: A pediatric neurosurgeon's vision
- Medical Device Tax: Are Conservatives' goals hampering repeal efforts?
- Personal health record use by adolescents
- Can Johnson & Johnson fire on all cylinders again?
- U.S. FDA to require proof of IEC 60601-1 3rd Edition in summer 2013
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
Navigation
NEWS
Johnson and Johnson executive splits for the corner office at Itamar Medical | Personnel Moves
J&J's former head of global cardiology makes the jump to CEO at Itamar Medical
Sunshine Heart seeks $25.5M in equity funding round | Wall Street Beat
Sunshine Heart raises $1.5 million of a hoped-for $25.5 million equity funding round.
J&J sues Shasta Technologies for logo infringement
J&J subsidiary Lifescan asks the courts to ban Shasta from using its logo, saying problems with...
Medical device tax: Theragenics, layoffs and the essence of the fight for repeal
Theragenics' recent rhetoric about the medical device tax captures many of the repeal movement's high...
FDA green-lights 1st HbA1cDx diabetes test | MassDevice.com On Call
U.S. healthcare regulators clear Roche's COBAS INTEGRA 800 Tina-quant HbA1cDx assay, the 1st HbA1c...
